Thrombosis and Hemostasis Research
Thrombosis is a crucial hemostatic process for maintaining blood volume (hemostasis) following injury, yet aberrant thrombosis can trigger pathological conditions including myocardial infarction and stroke. Therefore the initiation of thrombosis is tightly controlled under physiological conditions.
Thrombosis and Hemostasis Research Products Targets
- PI 3-kinase (22)
- Cell Adhesion Molecule (21)
- Others (7)
- Cyclooxygenase (24)
- PPARγ (16)
- PPARδ (5)
- PPARα (7)
- NK2 Receptor (7)
- NK1 Receptor (15)
- NK3 Receptor (5)
- Chemokine CXC Receptor (9)
- Chemokine CC Receptor (13)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- Purinergic (P2Y) Receptor (31)
- Protease-Activated Receptor (23)
- Phospholipase (16)
- Prostanoid Receptor (24)
- Phosphodiesterase (34)
Products for Thrombosis and Hemostasis Research
- Cat.No. Product Name Information/Activity
-
BCC3944
A 205804
A-205804 is an orally bioavailable, potent and selective lead inhibitor of E-selectin and ICAM-1 expression, with an IC50 of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.
-
BCC3946
A 286982
Potent inhibitor of the LFA-1/ICAM-1 interaction
-
BCC5826
Ac2-12
256447-08-2
-
BCC5825
Ac2-26
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue.
-
BCC3945
BIO 1211
Selective <span class='symbol'>α</span><sub>4</sub><span class='symbol'>β</span><sub>1</sub> (VLA-4) inhibitor
-
BCC8002
BIO 5192
327613-57-0
-
BCC3942
Cilengitide
Cilengitide, a cyclic RGD-containing peptide, is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50s of 4 and 79 nM, respectively.
-
BCC5988
Echistatin, α1 isoform
154303-05-6
-
BCC6998
GR 144053 trihydrochloride
1215333-48-4
-
BCC5938
KF 38789
257292-29-8
